Below are the top 10 Pharmaceutical stocks with highest upside potential,
UPDATED TODAY before 4:30 AM ET, based on the difference between current price
and Wall Street analysts average target price. One Chinese company (CBP) is on
the list. Marina Biotech, Inc. (NASDAQ:MRNA) has the 1st highest upside
potential in this segment of the market. Its upside is 354.8%. Its consensus
target price is $2.83 based on the average of all estimates. CytRx Corporation
(NASDAQ:CYTR) has the 2nd highest upside potential in this segment of the
market. Its upside is 258.9%. Its consensus target price is $3.00 based on the
average of all estimates. Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) has the
3rd highest upside potential in this segment of the market. Its upside is
244.8%. Its consensus target price is $7.00 based on the average of all
estimates. PharmAthene, Inc. (AMEX:PIP) has the 4th highest upside potential in
this segment of the market. Its upside is 238.5%. Its consensus target price is
$11.00 based on the average of all estimates. Prana Biotechnology Limited (ADR)
(NASDAQ:PRAN) has the 5th highest upside potential in this segment of the
market. Its upside is 233.3%. Its consensus target price is $8.00 based on the
average of all estimates. China Botanic Pharmaceutical Inc (AMEX:CBP) has the
6th highest upside potential in this segment of the market. Its upside is
205.0%. Its consensus target price is $4.88 based on the average of all
estimates. AVANIR Pharmaceuticals (NASDAQ:AVNR) has the 7th highest upside
potential in this segment of the market. Its upside is 203.8%. Its consensus
target price is $12.00 based on the average of all estimates. GenVec, Inc.
(NASDAQ:GNVC) has the 8th highest upside potential in this segment of the
market. Its upside is 201.2%. Its consensus target price is $1.13 based on the
average of all estimates. EpiCept Corporation (NASDAQ:EPCT) has the 9th highest
upside potential in this segment of the market. Its upside is 194.1%. Its
consensus target price is $2.00 based on the average of all estimates. XOMA
Limited (NASDAQ:XOMA) has the 10th highest upside potential in this segment of
the market. Its upside is 193.3%. Its consensus target price is $8.80 based on
the average of all estimates.
No comments:
Post a Comment